[{"address1": "3805 Old Easton Road", "city": "Doylestown", "state": "PA", "zip": "18902", "country": "United States", "phone": "617 463 9385", "website": "https://www.aprea.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.", "fullTimeEmployees": 7, "companyOfficers": [{"maxAge": 1, "name": "Dr. Oren  Gilad Ph.D.", "age": 55, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 796950, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John P. Hamill CPA", "age": 59, "title": "Senior VP, CFO, Principal Accounting Officer & Secretary", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 610230, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dansu  Li Ph.D.", "title": "Head of Technology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lars B. Abrahmsen Ph.D.", "age": 66, "title": "Senior VP & Chief Scientific Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Wiley", "age": 55, "title": "Senior Vice President of Corporate Development & Strategy", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michel  Afargan Ph.D.", "title": "Head of Pharmacology Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ze'ev  Weiss B.Sc., C.P.A.", "age": 61, "title": "Chief Business Advisor", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nadeem Q. Mirza M.D., M.P.H.", "title": "Executive Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea  Epstein", "title": "Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1730073600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.24, "open": 4.34, "dayLow": 3.92, "dayHigh": 4.42, "regularMarketPreviousClose": 4.24, "regularMarketOpen": 4.34, "regularMarketDayLow": 3.92, "regularMarketDayHigh": 4.42, "beta": 1.897, "forwardPE": -3.931373, "volume": 13509, "regularMarketVolume": 13509, "averageVolume": 22129, "averageVolume10days": 36930, "averageDailyVolume10Day": 36930, "marketCap": 23085572, "fiftyTwoWeekLow": 2.15, "fiftyTwoWeekHigh": 8.847, "priceToSalesTrailing12Months": 18.096594, "fiftyDayAverage": 3.29984, "twoHundredDayAverage": 4.745425, "currency": "USD", "enterpriseValue": -5601700, "floatShares": 3977294, "sharesOutstanding": 5431900, "sharesShort": 15177, "sharesShortPriorMonth": 10410, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0028, "heldPercentInsiders": 0.1175, "heldPercentInstitutions": 0.43847, "shortRatio": 0.55, "shortPercentOfFloat": 0.0038, "impliedSharesOutstanding": 5757000, "bookValue": 4.707, "priceToBook": 0.85192275, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -12927912, "trailingEps": -3.01, "forwardEps": -1.02, "lastSplitFactor": "1:20", "lastSplitDate": 1676246400, "enterpriseToRevenue": -4.391, "enterpriseToEbitda": 0.395, "52WeekChange": 0.12640452, "SandP52WeekChange": 0.3464489, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "APRE", "underlyingSymbol": "APRE", "shortName": "Aprea Therapeutics, Inc.", "longName": "Aprea Therapeutics, Inc.", "firstTradeDateEpochUtc": 1570109400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9a8f76c4-98d0-37f2-b77b-05a35baa6936", "messageBoardId": "finmb_329831339", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.01, "targetHighPrice": 20.0, "targetLowPrice": 11.0, "targetMeanPrice": 15.67, "targetMedianPrice": 16.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 28694694, "totalCashPerShare": 5.283, "ebitda": -14176494, "quickRatio": 9.274, "currentRatio": 9.553, "totalRevenue": 1275686, "revenuePerShare": 0.29, "returnOnAssets": -0.30255, "returnOnEquity": -0.50108004, "freeCashflow": -9356979, "operatingCashflow": -13559135, "revenueGrowth": 1.249, "operatingMargins": -6.8502502, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]